Scholar Rock Holding Corporation is a biopharmaceutical company developing monoclonal antibody treatments based on its expertise in growth factor activation within the TGFß superfamily. The company's pipeline includes Apitegromab (in Phase 2 trials for spinal muscular atrophy and muscular dystrophy), SRK-439 and SRK-181 (in earlier clinical stages for neuromuscular and cancer indications), and several preclinical programs targeting fibrotic diseases and anemias. Founded in 2012 and based in Cambridge, Massachusetts, Scholar Rock focuses on rare and severe neuromuscular conditions as well as other difficult-to-treat diseases.

entry readiness 53 · MODERATE · exit proximity 0

Value area 46.07–57.15 · 82% of 120d volume overhead · heavy supply